Colonoscopy Clinical Trials

Clinical trials related to Colonoscopy Procedure

Integrated Precision Imaging for Rectal Cancer Patients Undergoing Total Neoadjuvant Therapy: Hyperpolarized 13C-MRI, Metabolomics, and Radiomics

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This study is testing new imaging and analysis methods to improve how doctors predict treatment response in rectal cancer patients receiving chemoradiotherapy. Current MRI scans sometimes miss complete tumor response, which can lead to unnecessary surgery. To address this, researchers will use a special MRI technique called hyperpolarized carbon-13 MRI, along with blood and tissue analysis (metabolomics) and advanced image feature analysis (radiomics). These tools can track how cancer cells use energy and how metabolism changes during treatment. The study will follow 30 rectal cancer patients at Chang Gung Memorial Hospital over 3 years. Patients will undergo standard MRI, colonoscopy, and advanced metabolic imaging before and after treatment. Results will compare patients whose tumors completely respond to therapy with those who do not. The goal is to see if metabolic changes detected by hyperpolarized MRI and metabolomics can predict treatment outcomes earlier and more accurately. This may help doctors avoid unnecessary surgery and provide more personalized care for rectal cancer patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: t
View:

• Patients with biopsy proved rectal adenocarcinoma.

• Patents will undergo neoadjuvant chemoradiation therapy (nCRT).

• Patients more than 20-year-old.

Locations
Other Locations
Taiwan
Chang Gung Memorial hospital
RECRUITING
Taoyuan
Contact Information
Primary
Ying-Chieh Lai, MD
cappolya@gmail.com
+88633281200
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2028-07-30
Participants
Target number of participants: 30
Treatments
Pathological Complete Response (pCR)
Patients whose rectal cancer shows no residual tumor cells after neoadjuvant chemoradiotherapy, confirmed by pathology.
Non-Complete Response (non-pCR)
Patients whose rectal cancer still shows residual tumor cells after neoadjuvant chemoradiotherapy, confirmed by pathology.
Related Therapeutic Areas
Sponsors
Leads: Chang Gung Memorial Hospital
Collaborators: Ministry of Science and Technology, Taiwan

This content was sourced from clinicaltrials.gov